Deciphering ligand dependent degree of binding site closure and its implication in inhibitor design: A modeling study on human adenosine kinase
Introduction
Human Adenosine Kinase (AK), a promising therapeutic drug target [1], [2] against a variety of diseases including hypertension [3], epilepsy [4], pain [5], [6], diabetes [7], and inflammation [8], [9], has recently attracted great interest in the search of potent and selective inhibitors. Inhibition of AK results in increased intracellular adenosine, which passes out of the cell via passive diffusion or via nucleoside transporter(s) to activate nearby cell-surface adenosine receptors and produce a wide variety of therapeutically beneficial activities against the said diseases [10], [11]. There are a number of reports on synthesis, SAR [12], [13] and QSAR studies of nucleosidic analogues as AK inhibitors [14], [15]. Nucleoside kinases, such as AK, cytidine kinase, thymidine kinase, catalyze phosphorylation of a variety of nucleosides, including nucleoside-based drugs, giving rise to nucleoside-5′-O-phosphates which are incorporated into RNA or DNA via the corresponding triphosphates [16]. Thus, 5′-O-phosphates of these nucleosides are responsible not only for the pharmacological activity but also for their cytotoxic side effects [12]. Therefore, designing molecules having different scaffold than the nucleosides is demanding. With the objective of finding new scaffolds, docking and pharmacophore analysis were carried out. In the present study, we have discussed and illustrated the crucial interactions for inhibition and proposed a rationale for new inhibitor design.
Two categories of compounds are known as inhibitors of AK, nucleosides [17] and non-nucleosides [18]. In an earlier study, a pharmacophore model for nucleoside and non-nucleoside AK inhibitors was developed, considering their similar binding modes [19]. Like other ribokinase family members, adenosine kinase undergoes large conformational changes as a result of ligand binding [20]. Recently, it has been found that nucleoside and non-nucleoside inhibitors bind in two different, closed and open conformations of enzyme, respectively. [20]. Nucleoside binding triggers a hinge bending by Glycine-Glycine (GG) switch on account of sugar anchoring with the apo form of enzyme.
The present study involves a series of aryl and non-aryl nucleosidic inhibitors (tubercidins) with varying degrees of substitutions at C4 and C5 positions (Table 1) [12], [13]. Based on an exhaustive docking analysis, using various parameterizations, we have found that due to larger size than the required size in the closed binding site, aryl nucleoside analogues cannot accommodate in the closed binding site as adenosine. This study has illustrated that even all nucleosidic inhibitors cannot bind in similar fashion in the adenosine binding site. Hence, a need for another relaxed conformation of protein was realized. Earlier report on the existence of semi-open conformation of T. gondii AK [21], a homologue of human AK, tempted us to further explore the binding of larger tubercidins in semi-open form of human AK. Ligand induced semi-open form of binding site is also reported recently in case of HIV–RT [22], [23].
In this report we have proposed for the first time that, like T. gondii AK, human adenosine kinase also possesses a semi-open/semi-close conformation to accommodate the larger analogues. The docking results indicate that the key ligand–protein interactions are same for all tubercidin inhibitors, irrespective of their binding to close or semi-open protein conformations, thereby preserving all crucial interactions for activity. We started this study by presuming that only aryl molecules can not bind in the adenosine binding site due to large aryl groups at C4 and C5 position but at the end we could find that it is not only the presence of aryl groups, instead, few spatial requirements force the molecules to bind in different ways in the active site. Presence of large hydrophobic aromatic group at C4 position of the ligands has been predicted to be the main discriminating factor for separating the aryl binders from the non-aryl binders.
Again by comparing the interactions of nucleosides with those of non-nucleosidic inhibitors, we have analyzed the importance of some interactions, which are conserved for all the molecules interacting with the enzyme and play important role in molecular recognition. For all kinds of inhibitors and protein conformations, three separate pharmacophore models for lead identification have been generated. The interpretation of binding interactions was carried out in the light of pharmacophore modeling data. Coherent result for diverse binding patterns of inhibitors was obtained by 2D descriptor based cluster analysis. We have also discussed why and how molecules choose the mode of binding and in what way the information could be utilized for designing new inhibitors. The pharmacophore models were validated and finally used as queries for 3D database mining.
Thus to gain more insight into structure–activity relationships we carried out this docking and pharmacophore analysis. More importantly, we have shown that information encoded in this approach can be effective to create virtual libraries for selectively targeting particular conformation of protein. Incorporation of this knowledge into virtual screening queries represents a much wider chemical space of molecules, which could be identified as potent AK inhibitors.
Section snippets
Preparation of proteins and ligands
Adenosine and tubercidin analogues are known to bind similarly in the same binding site [24]. Comparison of AK bound to 5-iodotubercidin (PDB code 2I6A) and to adenosine (PDB code 1BX4) shows that the iodine atom of 5-iodotubercidin in 2I6A replaces a conserved and highly stabilized water molecule, which is present in 1BX4, deeply buried into the pocket. Adenosine binding induces protein closing, and subsequent retention of two water molecules W1 and W2 (near C4 and C5 substituents,
Overall docking results, binding mode prediction and analysis of scores
To assess the ability of docking strategy, ADO was initially docked as a control and the result was compared with the crystal structure of the enzyme inhibitor complex (1BX4). A docked structure of ADO, the natural substrate, in the protein (Fig. 1a) reveals all interactions of bound mode in 1BX4, with RMSD less than 0.5 Å, in all the four docking runs. The validity of GOLD protocol for the water system was assessed by docking 5-iodotubercidin (compound 2 in Table 1) into protein (1BX4 after
Conclusions
The purpose of this study was (1) to know the binding modes within the tubercidin analogues, (2) generate pharmacophores for validation of different binding modes for tubercidins and utilization of those pharmacophores as search tools to identify potent chemical entities. This work illustrates that the molecules of same chemical series, having different degrees of substitutions, bind to different protein conformations, showing similar interactions. As far our knowledge, this is the first report
Acknowledgements
The authors thank Council of Scientific and Industrial Research (CSIR), New Delhi, for providing financial grant under Mission Mode Program CMM 0017. SB thanks UGC for Senior Research Fellowship. We wish to thank Dr Peter Carlqvist and Gary Battle from CCDC for the useful suggestions, Katalin Nadassy from Accelrys for helping on some matters while dealing with Catalyst.
References (47)
Adenosine kinase, epilepsy and stroke: mechanisms and therapies
Trends Pharmacol. Sci.
(2006)- et al.
Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices
Neuropharmacology
(1994) - et al.
A CoMSIA study on the adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues
Bioorg. Med. Chem.
(2008) - et al.
A TOPS-MODE approach to predict adenosine kinase inhibition
Bioorg. Med. Chem. Lett.
(2004) - et al.
Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations
Bioorg. Med. Chem.
(2008) - et al.
Utilising structural knowledge in drug design strategies: applications using Relibase
J. Mol. Biol.
(2003) - et al.
4-Amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors
Bioorg. Med. Chem.
(2007) - et al.
Crystal structures of toxoplasma gondii adenosine kinase reveal a novel catalytic mechanism and prodrug binding
J. Mol. Biol.
(2000) - et al.
FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties
J. Mol. Biol.
(2001) - et al.
Comparative protein modeling by satisfaction of spatial restraints
J. Mol. Biol.
(1993)
Development and validation of a genetic algorithm for flexible docking
J. Mol. Biol.
Virtual ligand screening: strategies, perspectives and limitations
Drug Discov. Today
Adenosine as a modular of brain activity
Drug News Perspect.
Therapeutic potential of adenosine kinase inhibitors
Expert Opin. Investig. Drugs
Drugs modulating adenosine receptors as potential therapeutic agents for cardiovascular diseases
Expert Opin. Ther. Pat.
Purinergic modulation of pain
Rev. Analgesia
Adenosine and pain: recent findings with directly and indirectly acting agent
Drug Dev. Res.
Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes
Immunology
Recent developments in the discovery of novel adenosine kinase inhibitors: mechanism of action and therapeutic potential
CNS Drug Rev.
New adenosine kinase inhibitors with oral antiinflammatory activity
Drugs Future
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential
J. Med. Chem.
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition and antiseizure activity of 5-iodotubercidin analogues
J. Med. Chem.
Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition and antiseizure activity of diaryltubercidin analogues
J. Med. Chem.
Cited by (6)
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase
2016, Journal of Medicinal ChemistryMolecular shape analysis-guided virtual screening platform for adenosine kinase inhibitors
2016, Bioinformatics and Biology InsightsAdenosine kinase: Exploitation for therapeutic gain
2013, Pharmacological ReviewsTheoretical studies on the conformational change of adenosine kinase induced by inhibitors
2011, International Journal of Quantum Chemistry